PSC
APLS

Portman Square Capital’s Apellis Pharmaceuticals APLS Stock Holding History

Portman Square Capital’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-14,053
Closed -$841K – 311
2023
Q4 		$841K Sell
14,053
-32,079
-70% -$1.63M 0.02% 363
2023
Q3 		$1.75M Buy
+46,132
New +$2.03M 0.04% 317

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Portman Square Capital's APLS Position: Q1 2024 in Review

Portman Square Capital sold out of Apellis Pharmaceuticals (APLS) in Q1 2024, closing a stake of 14,053 shares — an estimated $841K sold.

Portman Square Capital first reported a position in APLS in Q3 2023 and held it in 2 quarters. The position peaked at $1.75M in Q3 2023. 302 funds tracked by Wall St. Rank hold APLS as of Q1 2024.

  • Portman Square Capital reported no remaining Apellis Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Portman Square Capital sold 14,053 Apellis Pharmaceuticals shares in Q1 2024, an estimated $841K.
  • Portman Square Capital first reported a position in Apellis Pharmaceuticals in Q3 2023 and held it in 2 quarters.
  • Portman Square Capital's Apellis Pharmaceuticals position peaked at $1.75M in Q3 2023.
  • 302 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2024.

Based on Portman Square Capital's 13F filing for Q1 2024, filed 15 Apr 2024.